Search company, investor...
Search
ista company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ista.com

Founded Year

1957

Stage

Acquired | Acquired

Valuation

$0000 

About ista

ista is a provider in the submetering industry - the measurement of energy and water consumption and the cost allocation for multi-occupant properties. ista sells a range of meter hardware as well as providing a package of related services, such as maintenance, meter reading, data processing and billing. In addition, the company is expanding its service range, offering energy management for utility customers. ista is primarily a service company that uses hardware sales as a means to generate service revenues.

ista Headquarters Location

Grugaplatz 2

Essen, D-45131,

Germany

+49 (0)201 459-02

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ista Patents

ista has filed 5 patents.

The 3 most popular patent topics include:

  • Computer network security
  • Computer security
  • Computer security exploits
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/28/2017

8/23/2022

Computer network security, Computer security, Data security, Computer security exploits, Privacy

Grant

Application Date

3/28/2017

Grant Date

8/23/2022

Title

Related Topics

Computer network security, Computer security, Data security, Computer security exploits, Privacy

Status

Grant

Latest ista News

12:26 EDT FDA Accepts Integral Molecular's Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTA...

Sep 7, 2022

News provided by Share this article Share this article PHILADELPHIA, Sept. 7, 2022 /PRNewswire/ -- Integral Molecular, the leader in antibody discovery against membrane proteins, has been accepted into the U.S. Food & Drug Administration (FDA)'s ISTAND pilot program. This program supports Innovative Science and Technology Approaches for New Drugs and was created to expand the drug development tool types listed in the 21st Century Cures legislation. A major goal of the pilot program is to qualify these tools, thus facilitating regulatory review by allowing them to be used in regulatory (IND, NDA or BLA) applications without needing the FDA to reconsider and reconfirm their suitability. Despite their reputation for 'exquisite specificity', antibodies and antibody-based therapies, such as CAR-T cells, frequently demonstrate unexpected off-target binding. Integral Molecular's Membrane Proteome Array (MPA) for antibody specificity and safety profiling intends to address ICH-FDA's in vitro testing recommendations to assess unintended binding of monoclonal antibodies that can result in safety and toxicity issues. The MPA is one of the largest collections of membrane proteins used for specificity profiling of antibody-based therapeutics, with over 6,000 native-conformation membrane proteins encompassing nearly the entire human membrane proteome. This technology is intended to be compatible with numerous biotherapeutic modalities, including monoclonal antibodies, bispecifics, and CAR-T therapeutics. "We are thrilled to be working with the FDA's ISTAND program," said Benjamin Doranz, CEO of Integral Molecular. "We share the FDA's interest in developing in vitro technologies to better assess the safety of antibody drugs at an earlier and less costly stage of development." FDA has posted a statement on this LOI acceptance to the ISTAND Pilot Program: https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements#statements About Integral Molecular Integral Molecular ( integralmolecular.com ) is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses. Follow Integral Molecular on  LinkedIn Follow Integral Molecular on  Twitter Press Contact:

  • When was ista founded?

    ista was founded in 1957.

  • Where is ista's headquarters?

    ista's headquarters is located at Grugaplatz 2, Essen.

  • What is ista's latest funding round?

    ista's latest funding round is Acquired.

  • Who are the investors of ista?

    Investors of ista include Cheung Kong Infrastructure Holdings, CVC Capital Partners and Charterhouse Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.